A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

Factor XIIa antagonist monoclonal antibody

Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use

DRUG

Placebo

Buffer without active ingredient

Trial Locations (16)

2560

Campbelltown Hospital, Campbelltown

10029

The Mount Sinai Hospital, New York

10117

Charité Universitätsmedizin Berlin, Berlin

17033

Pennsylvania State University, Hershey

20815

Institute for Asthma and Allergy, Chevy Chase

55131

Hautklinik und Poliklinik der Universitätsklinik Mainz, Mainz

60590

Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt

64546

HZRM Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf

75231

AARA Research Center, Dallas

80112

Immunoe Health Centers, Centennial

92868

Donald S. Levy, Orange

94598

Allergy & Asthma Clinical Research, Walnut Creek

7830604

Barzilai University Medical Center, Ashkelon

T6G 2B7

University of Alberta, Edmonton

L8S 4K1

Allergy and Clinical Immunology McMaster University, Hamilton

K1G 6C6

Ottawa Allergy Research Corp, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY